全文获取类型
收费全文 | 1457篇 |
免费 | 46篇 |
国内免费 | 11篇 |
学科分类
医药卫生 | 1514篇 |
出版年
2015年 | 8篇 |
2014年 | 7篇 |
2013年 | 13篇 |
2010年 | 28篇 |
2009年 | 28篇 |
2007年 | 13篇 |
2006年 | 11篇 |
2001年 | 8篇 |
1999年 | 15篇 |
1998年 | 30篇 |
1997年 | 31篇 |
1996年 | 31篇 |
1995年 | 15篇 |
1994年 | 34篇 |
1993年 | 40篇 |
1992年 | 30篇 |
1991年 | 17篇 |
1990年 | 24篇 |
1989年 | 35篇 |
1988年 | 32篇 |
1987年 | 30篇 |
1986年 | 32篇 |
1985年 | 24篇 |
1984年 | 22篇 |
1983年 | 14篇 |
1982年 | 19篇 |
1981年 | 22篇 |
1980年 | 18篇 |
1979年 | 13篇 |
1978年 | 9篇 |
1977年 | 8篇 |
1976年 | 13篇 |
1975年 | 10篇 |
1974年 | 11篇 |
1973年 | 9篇 |
1972年 | 7篇 |
1968年 | 9篇 |
1965年 | 12篇 |
1964年 | 11篇 |
1963年 | 9篇 |
1961年 | 7篇 |
1960年 | 10篇 |
1959年 | 57篇 |
1958年 | 102篇 |
1957年 | 102篇 |
1956年 | 98篇 |
1955年 | 100篇 |
1954年 | 110篇 |
1949年 | 29篇 |
1948年 | 61篇 |
排序方式: 共有1514条查询结果,搜索用时 156 毫秒
61.
62.
S. D. ANDERSON 《Internal medicine journal》1984,14(S3):803-806
63.
64.
65.
66.
RONALD WELLS M.D. PAUL KHAIRY M.D. Ph .D.† LOUISE HARRIS M.D. ‡ C. CHRISTIAN ANDERSON M.D. § SESHADRI BALAJI M.B.B.S. M.R.C.P. Ph .D. 《Pacing and clinical electrophysiology : PACE》2009,32(10):1313-1318
Background: Very little is known about use of the class III antiarrhythmic dofetilide in patients with congenital heart disease (CHD).
Methods: A multicenter retrospective review of experience with dofetilide in CHD patients was undertaken.
Results: Twenty adults with CHD and refractory atrial arrhythmias were treated with dofetilide at four institutions over a 7-year period. Three (15%) experienced adverse effects during in-hospital initiation of dofetilide (two with torsade de pointes, one with excessive QTc prolongation) and were not continued on this therapy. The remaining 17 were discharged taking dofetilide, with either resolved or improved arrhythmia. One was lost to follow-up. Five subsequently discontinued dofetilide due to waning effectiveness, manifest by recurrence of their arrhythmias. Eleven (55%) remained on dofetilide at most recent visit, with a median follow-up of nearly 1 year. Seven of these 11, or 35% of the CHD patients originally started on dofetilide, experienced a complete resolution of their arrhythmia. The remaining four had breakthrough episodes of atrial arrhythmia, but remained on dofetilide. No patient experienced torsade de pointes after the in-hospital initiation period.
Conclusions: Used appropriately, dofetilide appears to be a viable adjunct to catheter-based ablation and alternative pharmacological approaches for the treatment of atrial arrhythmias in adult patients with congenital heart disease. 相似文献
Methods: A multicenter retrospective review of experience with dofetilide in CHD patients was undertaken.
Results: Twenty adults with CHD and refractory atrial arrhythmias were treated with dofetilide at four institutions over a 7-year period. Three (15%) experienced adverse effects during in-hospital initiation of dofetilide (two with torsade de pointes, one with excessive QTc prolongation) and were not continued on this therapy. The remaining 17 were discharged taking dofetilide, with either resolved or improved arrhythmia. One was lost to follow-up. Five subsequently discontinued dofetilide due to waning effectiveness, manifest by recurrence of their arrhythmias. Eleven (55%) remained on dofetilide at most recent visit, with a median follow-up of nearly 1 year. Seven of these 11, or 35% of the CHD patients originally started on dofetilide, experienced a complete resolution of their arrhythmia. The remaining four had breakthrough episodes of atrial arrhythmia, but remained on dofetilide. No patient experienced torsade de pointes after the in-hospital initiation period.
Conclusions: Used appropriately, dofetilide appears to be a viable adjunct to catheter-based ablation and alternative pharmacological approaches for the treatment of atrial arrhythmias in adult patients with congenital heart disease. 相似文献
67.
Robert J. HANCOX Peter N. LE SOUËF Gary P. ANDERSON Helen K. REDDEL Anne B. CHANG Richard BEASLEY 《Respirology (Carlton, Vic.)》2010,15(2):194-201
Despite major advances in the understanding of the pathogenesis of asthma and improvements in management, the accompanying benefits from public health initiatives and clinical practice have arguably been less than expected. For example, there are no effective public health strategies or treatment regimes that reduce the risk of developing asthma or influence its natural history. These represent priority areas for future translational research, which would need to investigate genetic and environmental interactions and vaccine strategies. In terms of asthma management it is tempting to focus on novel drug therapies; however, a case can be made that the priority is to undertake research that leads to improvements in the use of existing treatments through public health and primary care initiatives. Guidelines represent an important component of this approach, with recommendations for asthma imbedded within respiratory guidelines that can be implemented in the developing world where other acute and chronic respiratory disorders are common. This approach offers the best opportunity to close the gap between what is currently achieved in asthma management and that which is potentially achievable. 相似文献
68.
NKANYEZI E. NGWENYAMA BS JOHN ANDERSON MD DANIEL G. HOERNSCHEMEYER MD JOSEPH D. TOBIAS MD 《Paediatric anaesthesia》2008,18(12):1190-1195
Introduction: Total intravenous anesthesia with propofol and a synthetic opioid is a frequently chosen anesthetic technique for posterior spinal fusion. Despite its utility, adverse effects may occur with high or prolonged propofol dosing regimens including delayed awakening. The current study investigated the propofol‐sparing effects of the concomitant administration of the α2‐adrenergic agonist, dexmedetomidine, during spinal fusion surgery in adolescents. Methods: The surgical database of the department of orthopedic surgery was searched and patients (12–21 years of age) were identified who had undergone spinal fusion for either idiopathic or neuromuscular scoliosis during the past 24 months. Patients were assigned to two groups. Group 1 included patients anesthetized with propofol and remifentanil and group 2 included patients anesthetized with dexmedetomidine, propofol, and remifentanil. In the latter group, dexmedetomidine was administered as a continuous infusion of 0.5 μg·kg?1·h?1 started after the induction of anesthesia without a loading dose. Propofol was adjusted to maintain the bispectral index (BIS) number at 40–50 and remifentanil was adjusted to maintain the mean arterial pressure (MAP) at 50–65 mmHg. Labetolol or hydralazine was used if the MAP could not be maintained at 50–65 mmHg with remifentanil up to a maximum dose of 0.6 μg/kg/min. Statistical analysis included a nonpaired t‐test for parametric data (age, weight, remifentanil/propofol infusion requirements, and heart rate/blood pressure values). A nonparametric statistical analysis (Dunn) was used to compare BIS numbers. Parametric data are presented as the mean ± sd while nonparametric data are presented as the median and the 95th percentile confidence intervals. Results: Twelve patients received propofol–remifentanil–dexmedetomidine and 24 received propofol–remifentanil. There were no differences in the demographic data, BIS numbers or hemodynamic parameters between the two groups. There was a reduction in the propofol infusion requirements in patients who also received dexmedetomidine (71 ± 11 μg·kg?1·min?1) compared with those receiving only propofol–remifentanil (101 ± 33 μg·kg?1·min?1, P = 0.0045). No difference was noted in the remifentanil infusion requirements or the use of supplemental agents (hydralazine and labetolol) to maintain controlled hypotension. Conclusion: The concomitant use of dexmedetomidine in patients undergoing spinal fusion reduces propofol infusion requirements when compared with those patients receiving only propofol and remifentanil. 相似文献
69.
70.
Intestinal absorption, metabolism and effects of bacterial chemotactic peptides in rat intestine 总被引:1,自引:0,他引:1
A. F. WOODHOUSE R. P. ANDERSON D. B. MYERS M. F. BROOM C. H. HOBSON V. S. CHADWICK 《Journal of gastroenterology and hepatology》1987,2(1):35-43
N -formylated chemotactic peptides are produced by intestinal bacteria in vitro and Can be detected in intestinal luminal fluids. The healthy intestine must have mechanisms for preventing absorption of such peptides which can induce an inflammatory response when introduced systemically. Synthetic formyl-methionyl-leucyl-phenylalanine ( F -met-leu-3 H-phe) has been used as a model bacterial chemotactic peptide to investigate intestinal absorption and metabolism of such peptides in the rat. Disappearance of tritium-activity was rapid from jejunal and ileal loops and substantial hydrolysis of peptide occurred with only labelled metabolites appearing in portal blood. Less absorption and less metabolism occurred in the colon. Degradation of F -met-leu-phe was due to a mucosal carboxypeptidase and was inhibited by benzylsuccinate, a potent inhibitor of the enzyme. In the presence of inhibitor, luminal disappearance from ileal loops was abolished and F -met-leu-3 H-phe was not detected in portal blood indicating that healthy gut mucosa is 'impermeable' to intact peptide. The intestinal 'barrier' preventing mucosal penetration and the inflammatory effects of luminal bacterial peptides have two components: restricted mucosal permeability and a carboxypeptidase capable of hydrolysing such peptides with loss of their bioactivity. 相似文献